| 1.25 Delayed Data As of May 17 |  -0.05 / -3.85%Today’s Change | 0.60 Today|||52-Week Range 3.10 | +28.87% Year-to-Date |
| Vascular Biogenics (VBLT) Reports Q1 Loss, Misses Revenue Estimates May 15 / Zacks.com - Paid Partner Content | Will Vascular Biogenics (VBLT) Report Negative Earnings Next Week? What You Should Kn... May 08 / Zacks.com - Paid Partner Content |
| Previous close | 1.30 |
| Today’s open | 1.30 |
| Day’s range | 1.25 - 1.31 |
| Volume | 50,023 |
| Average volume (3 months) | 132,487 |
| Market cap | $45.9M |
| Earnings growth (last year) | -67.70% |
| Earnings growth (this year) | +14.52% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -95.78% |
| P/E ratio | NM |
| Price/Sales | 54.67 |
| Price/Book | 0.87 |
| Today’s change | Today’s % change | |
|---|---|---|
| EVGNEvogene Ltd | +0.04 | +2.29% |
| ICCCImmuCell Corp | -0.08 | -1.27% |
| BPTHBio Path Holdings In... | -1.23 | -7.34% |
| CLSNCelsion Corp | -0.01 | -0.47% |
| Next reporting date | August 15, 2019 |
| EPS forecast (this quarter) | -$0.15 |
| Annual revenue (last year) | $585.0K |
| Annual profit (last year) | -$20.5M |
| Net profit margin | -3,497.09% |
Sector Health Technology |
Industry Biotechnology |
Chief Executive Officer & Director Dror Harats |
Vice President-Research & Operations Eyal Breitbart |
Corporate headquarters Modi'in, Jerusalem |
